A randomized, double-blind, placebo-controlled, multi-centre phase IIa study evaluating the safety and tolerability of IRL752 in patients with Parkinson's Disease Dementia.

Trial Profile

A randomized, double-blind, placebo-controlled, multi-centre phase IIa study evaluating the safety and tolerability of IRL752 in patients with Parkinson's Disease Dementia.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs IRL 752 (Primary)
  • Indications Attention-deficit hyperactivity disorder; Dementia
  • Focus Adverse reactions
  • Sponsors Integrative Research Laboratories
  • Most Recent Events

    • 04 Nov 2017 According to an Integrative Research Laboratories media release, dosing has been initiated in this trial.
    • 05 Oct 2017 According to an Integrative Research Laboratories media release, the company has received approval from Fimea (the Finnish MPA) and the Ethics Committee at the University hospital in Turkku to conduct this trial in Finland.
    • 04 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top